Journal ArticleMov Disord Clin Pract · February 2025
BACKGROUND: The MDS-UPDRS Parts IB and II are self-reported items providing a direct patient voice to the experiences of PD. OBJECTIVE: To determine the most sensitive combination of MDS-UPDRS Parts IB and II items that accurately predicted the clinically ...
Full textLink to itemCite
Journal ArticleParkinsonism Relat Disord · November 2024
INTRODUCTION: Tracking of emergent symptoms (ES) in de novo Parkinson Disease (PD) patients using Parts Ib and II of the MDS-UPDRS rating scale has been proposed as an outcome measure for PD clinical trials, based on observations in the Safety, Tolerabilit ...
Full textLink to itemCite
Journal ArticleAJNR. American journal of neuroradiology · November 2024
Background and purposeTo develop and evaluate an automated, AI-based, volumetric brain tumor MRI response assessment algorithm on a large cohort of patients treated at a high-volume brain tumor center.Materials and methodsWe retrospective ...
Full textCite
Journal ArticleEBioMedicine · July 2024
BACKGROUND: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with traditional endocrine therapy (ET) are now the recommended first-line treatment for hormone receptor (HR)-positive and HER2-negative metastatic breast cancer (MBC). However, th ...
Full textLink to itemCite
Journal ArticleAlzheimers Dement (N Y) · 2024
INTRODUCTION: Alzheimer's disease (AD) is a neurodegenerative disorder characterized by declines in cognitive and functional severities. This research utilized the Clinical Dementia Rating (CDR) to assess the influence of tilavonemab on these deterioration ...
Full textOpen AccessLink to itemCite
Journal ArticleAnn Appl Stat · September 2023
Alzheimer's disease (AD) is a complex neurological disorder impairing multiple domains such as cognition and daily functions. To better understand the disease and its progression, many AD research studies collect multiple longitudinal outcomes that are str ...
Full textOpen AccessLink to itemCite
Journal ArticleStat Med · May 10, 2023
Alzheimer's Disease (AD) is the leading cause of dementia and impairment in various domains. Recent AD studies, (ie, Alzheimer's Disease Neuroimaging Initiative (ADNI) study), collect multimodal data, including longitudinal neurological assessments and mag ...
Full textOpen AccessLink to itemCite
Journal ArticleJ Prev Alzheimers Dis · 2023
BACKGROUND: The 523 poly-T length polymorphism (rs10524523) in TOMM40 has been reported to influence longitudinal cognitive test performance within APOE ε3/3 carriers. The results from prior studies are inconsistent. It is also unclear whether specific APO ...
Full textOpen AccessLink to itemCite
Journal ArticleCPT Pharmacometrics Syst Pharmacol · October 2022
The Movement Disorder Society revised version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) parts 2 and 3 reflect patient-reported functional impact and clinician-reported severity of motor signs of Parkinson's disease (PD), respectively. Tot ...
Full textOpen AccessLink to itemCite
ConferenceMovement disorders : official journal of the Movement Disorder Society · September 2022
BackgroundLongitudinal item response theory (IRT) models previously suggested that the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor examination has two salient domains, tremor and nontremor, that progress in ...
Full textOpen AccessCite
Journal ArticleStat Med · December 30, 2021
Alzheimer's disease (AD) is a severe neurodegenerative disorder impairing multiple domains, for example, cognition and behavior. Assessing the risk of AD progression and initiating timely interventions at early stages are critical to improve the quality of ...
Full textOpen AccessLink to itemCite
Journal ArticleMov Disord Clin Pract · October 2021
BACKGROUND: Although nontremor and tremor Part 3 Movement Disorder Society-Unified Parkinson's Disease Rating Scale items measure different impairment domains, their distinct progression and drug responsivity remain unstudied longitudinally. The total scor ...
Full textOpen AccessLink to itemCite